对使用HeartMate 3的患者的结果进行分析,其中包括带有和没有右心室辅助器件支持的患者
Vinh Q Chau1, Laura Coyle1, Rachel Pedersen2
1Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, USA.
ESC heart failure
|June 25, 2025
概括
在HeartMate 3 (HM3) 左心室辅助装置 (LVAD) 植入后需要临时右心室辅助装置 (tRVAD) 支持的患者面临着显著更高的死亡率和不良事件风险. 这突出了管理复杂心力衰竭患者需要联合机械循环支持的关键考虑因素.
科学领域:
- 心血管外科心血管外科
- 机械循环支持 机械循环支持
- 心脏衰竭管理的管理
背景情况:
- 急性右心力衰竭是HeartMate 3 (HM3) 左心室辅助装置 (LVAD) 植入后的一个已知的并发症.
- 在HM3 LVAD患者中,与临时右心室辅助器件 (tRVAD) 支持相关的临床结果和特定风险尚未得到充分描述.
研究的目的:
- 检查和比较接受HM3 LVAD的患者的临床结果,根据随后的tRVAD支持的需要进行分层.
- 为了确定与HM3 LVAD和tRVAD联合治疗相关的风险因素和不良事件.
主要方法:
- 在2018年至2022年期间,对192名接受初级HM3 LVAD植入的患者进行了回顾性单中心研究.
- 根据需要因临床恶化而需要tRVAD支持 (同时或延迟) 患者被分类.
- 主要结局:使用竞争性风险分析分析的1年全因死亡率;次要结局包括通过匹配队列分析评估的中风和透析等不良事件.
主要成果:
- 26%的患者 (51/192) 需要tRVAD支持,经常出现更严重的疾病 (INTERMACS 概况1或2) 和之前的VA-ECMO使用.
- 与单独使用HM3 LVAD相比,tRVAD组的1年全因死亡率 (33%对3%) 和住院死亡率 (26%对1%) 显着更高.
- tRVAD患者面临中风 (HR 5.75) 和透析 (HR 13.4) 的风险增加;并发和延迟的tRVAD之间没有发现不良事件的显著差异.
结论:
- 需要tRVAD支持的HM3 LVAD患者显示死亡率和主要不良临床结果的风险大幅增加.
- 这些发现强调了复杂的管理和需要联合右室和左室机械支持的患者的高度脆弱性.
相关概念视频
Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
Cardiomyopathy III: Hypertrophic Cardiomyopathy
65
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
65
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Heart Failure III: Clinical Manifestations
59
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
59
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34


